By Stefanie Fogel and Maggie Craig

When the 2018 Farm Bill removed hemp from the definition of marijuana – and thus from the list of Schedule I drugs under the Controlled Substance Act (CSA) – it unlocked an industry ripe for expansion. Sales of products containing cannabidiol (CBD), are booming – indeed, analysts predict that CBD sales could become a $15-$20 billion industry by 2025.

However, CBD companies are still faced with a regulatory quagmire, struggling to understand how to legally promote, label, and distribute CBD consumables.

In this alert, we review the current state of the laws and regulations in the US, and look at the potential pathways to a viable resolution. At the least, safety will be a critical requirement, and industry will play an important part in developing the necessary body of evidence. Continue reading here.